Your browser is no longer supported. Please, upgrade your browser.
Settings
CBLI Cleveland BioLabs, Inc. daily Stock Chart
CBLI [NASD]
Cleveland BioLabs, Inc.
Index- P/E- EPS (ttm)-0.29 Insider Own58.14% Shs Outstand11.38M Perf Week-8.13%
Market Cap16.73M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.73M Perf Month1.38%
Income-3.30M PEG- EPS next Q- Inst Own5.30% Short Float0.62% Perf Quarter13.79%
Sales1.10M P/S15.21 EPS this Y63.10% Inst Trans-2.58% Short Ratio1.13 Perf Half Y-9.82%
Book/sh-0.20 P/B- EPS next Y- ROA-61.90% Target Price2.00 Perf Year-47.85%
Cash/sh0.29 P/C5.07 EPS next 5Y- ROE282.50% 52W Range1.00 - 3.16 Perf YTD45.54%
Dividend- P/FCF- EPS past 5Y47.00% ROI320.00% 52W High-53.48% Beta0.70
Dividend %- Quick Ratio3.70 Sales past 5Y-33.10% Gross Margin- 52W Low47.00% ATR0.10
Employees15 Current Ratio3.70 Sales Q/Q0.00% Oper. Margin- RSI (14)42.32 Volatility4.03% 6.38%
OptionableNo Debt/Eq- EPS Q/Q28.80% Profit Margin- Rel Volume0.04 Prev Close1.51
ShortableYes LT Debt/Eq- EarningsMay 28 BMO Payout- Avg Volume25.71K Price1.47
Recom- SMA20-5.14% SMA50-7.56% SMA200-11.62% Volume1,099 Change-2.49%
Jan-24-14Downgrade Oppenheimer Outperform → Perform
Mar-21-13Initiated Cantor Fitzgerald Buy $4
Dec-06-12Initiated Oppenheimer Outperform $3
Dec-04-12Initiated Burrill Institutional Research Mkt Outperform $4
Feb-02-11Initiated Wedbush Outperform $10
Oct-13-10Downgrade WBB Securities Strong Buy → Hold $6.50 → $6.50
Sep-17-10Reiterated Rodman & Renshaw Mkt Outperform $8 → $11
Jul-21-10Downgrade WBB Securities Strong Buy → Speculative Buy $6.50
Sep-29-09Initiated Rodman & Renshaw Mkt Outperform $8
May-25-19 08:15AM  M&T Bank crossed $4 billion revenue mark to remain top Buffalo-based public company American City Business Journals
May-15-19 08:30AM  Cleveland Biolabs Reports First Quarter 2019 Financial Results and Development Progress ACCESSWIRE
Mar-07-19 08:15AM  Cleveland Biolabs Reports 2018 Financial Results and Development Progress ACCESSWIRE +59.95%
Feb-07-19 11:58AM  Does Cleveland BioLabs, Inc. (NASDAQ:CBLI) Have A Particularly Volatile Share Price? Simply Wall St.
Dec-14-18 02:22PM  Genome Protection received $10.5M investment from fund controlled by Roman Abramovich American City Business Journals -5.52%
Dec-06-18 09:31AM  What does Cleveland BioLabs Incs (NASDAQ:CBLI) Balance Sheet Tell Us About Its Future? Simply Wall St.
Nov-23-18 07:20AM  Market Trends Toward New Normal in support, Innovative Solutions and Support, Cleveland BioLabs, Ideal Power, Comstock Holding Companies, and GWG Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire +6.97%
Nov-14-18 07:30AM  Cleveland Biolabs Reports Third Quarter 2018 Financial Results and Development Progress ACCESSWIRE
Oct-05-18 01:24PM  The Cleveland BioLabs Inc (NASDAQ:CBLI) Ownership Structure Could Be Important Simply Wall St.
Aug-14-18 05:15PM  Cleveland Biolabs Reports Second Quarter 2018 Financial Results And Development Progress ACCESSWIRE
04:45PM  Cleveland Biolabs Announces Formation and Financing of an Anti-Aging Joint Venture ACCESSWIRE
Aug-06-18 05:00PM  Cleveland BioLabs Announces Delay in Analysis of Biocomparability Data Required for Regulatory Submission ACCESSWIRE
Jun-22-18 03:12PM  Ikeas departure from Cary leads to impairment charge for mall owner American City Business Journals
Jun-12-18 07:30AM  Wired News Alnylam Pharma Presented New Encouraging Results from Phase-1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type-1 ACCESSWIRE
May-31-18 04:18PM  Should You Be Concerned About Cleveland BioLabs Incs (NASDAQ:CBLI) Investors? Simply Wall St.
May-15-18 08:00AM  Cleveland Biolabs Reports First Quarter 2018 Financial Results and Development Progress ACCESSWIRE
Apr-17-18 02:37PM  Is Cleveland BioLabs Incs (NASDAQ:CBLI) CEO Being Overpaid? Simply Wall St.
Mar-28-18 05:05PM  Cleveland Biolabs Announces Progress on European Marketing Authorization Application ACCESSWIRE
Mar-06-18 08:00AM  Cleveland Biolabs Reports 2017 Financial Results and Development Progress ACCESSWIRE
Feb-21-18 04:28PM  Should You Be Concerned About Cleveland BioLabs Incs (NASDAQ:CBLI) Investors? Simply Wall St.
Feb-09-18 02:02PM  Have Investors Already Priced In Healthcare Growth For Cleveland BioLabs Inc (NASDAQ:CBLI)? Simply Wall St.
Jan-01-18 02:45PM  Is Cleveland BioLabs Incs (NASDAQ:CBLI) CEO Incentives Align With Yours? Simply Wall St.
Dec-29-17 11:40AM  ETFs with exposure to Cleveland BioLabs, Inc. : December 29, 2017 Capital Cube
Dec-22-17 04:55PM  Is Cleveland BioLabs Inc (NASDAQ:CBLI) As Financially Strong As Its Balance Sheet Indicates? Simply Wall St. -7.32%
Dec-13-17 12:55PM  ETFs with exposure to Cleveland BioLabs, Inc. : December 13, 2017 Capital Cube +6.67%
Dec-01-17 07:00AM  Wired News FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular Dystrophy ACCESSWIRE +6.58%
Nov-30-17 01:36PM  ETFs with exposure to Cleveland BioLabs, Inc. : November 30, 2017 Capital Cube -6.54%
Nov-29-17 08:17AM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-22-17 08:40PM  What Does Cleveland BioLabs Incs (CBLI) Ownership Structure Look Like? Simply Wall St.
Nov-15-17 11:38AM  ETFs with exposure to Cleveland BioLabs, Inc. : November 15, 2017 Capital Cube
Nov-14-17 08:15AM  Cleveland BioLabs Reports Third Quarter 2017 Financial Results and Development Progress Marketwired -10.15%
Nov-08-17 04:49PM  How Does Cleveland BioLabs Inc (CBLI) Compare To The Healthcare Sector? Simply Wall St.
Oct-26-17 10:23AM  ETFs with exposure to Cleveland BioLabs, Inc. : October 26, 2017 Capital Cube
Oct-11-17 11:17AM  ETFs with exposure to Cleveland BioLabs, Inc. : October 11, 2017 Capital Cube
Sep-19-17 05:11PM  ETFs with exposure to Cleveland BioLabs, Inc. : September 19, 2017 Capital Cube
Sep-18-17 12:02PM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 Capital Cube
Sep-11-17 03:57PM  What You Must Know About Cleveland BioLabs Incs (CBLI) Risks Simply Wall St.
Aug-11-17 08:00AM  Cleveland Biolabs Countermeasure for Acute Radiation Syndrome, Pipeline Review, and Market Potential ACCESSWIRE -5.35%
Aug-04-17 07:26PM  ETFs with exposure to Cleveland BioLabs, Inc. : August 4, 2017 Capital Cube
Jul-12-17 02:18PM  ETFs with exposure to Cleveland BioLabs, Inc. : July 12, 2017 Capital Cube
Jun-26-17 03:32PM  ETFs with exposure to Cleveland BioLabs, Inc. : June 26, 2017 Capital Cube
Jun-16-17 03:31PM  ETFs with exposure to Cleveland BioLabs, Inc. : June 16, 2017 Capital Cube
Jun-05-17 02:06PM  ETFs with exposure to Cleveland BioLabs, Inc. : June 5, 2017 Capital Cube
Jun-02-17 10:27AM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-15-17 07:30AM  Cleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress Marketwired
Apr-20-17 08:00AM  Governments Looking at Cleveland Biolabs Radiation Countermeasure Accesswire
Apr-19-17 02:14PM  ETFs with exposure to Cleveland BioLabs, Inc. : April 19, 2017 Capital Cube
Apr-18-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Cleveland BioLabs and Infinity Pharmaceuticals Accesswire
Apr-17-17 07:36AM  Cleveland BioLabs Announces Commencement of In Vivo Biocomparability Study Marketwired
07:30AM  Cleveland BioLabs Announces European Medicines Agency Positive Opinion Regarding the Entolimod Pediatric Investigation Plan Marketwired
Apr-11-17 05:00PM  Cleveland BioLabs Announces Webcast of Annual Meeting Marketwired
Apr-07-17 04:05PM  ETFs with exposure to Cleveland BioLabs, Inc. : April 7, 2017 Capital Cube
Mar-17-17 12:04PM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Capital Cube
12:04PM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
Mar-14-17 02:58PM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
02:58PM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Feb-28-17 01:04PM  CLEVELAND BIOLABS INC Financials
Feb-22-17 04:21PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
04:15PM  Cleveland BioLabs Reports 2016 Financial Results and Development Progress Marketwired
Dec-07-16 11:24AM  ETFs with exposure to Cleveland BioLabs, Inc. : December 7, 2016 Capital Cube
11:24AM  ETFs with exposure to Cleveland BioLabs, Inc. : December 7, 2016
Nov-15-16 11:56AM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016
Nov-14-16 07:31AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
07:30AM  Cleveland BioLabs Reports Third Quarter 2016 Financial Results and Development Progress Marketwired
Oct-11-16 08:46AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme
08:45AM  Cleveland BioLabs Announces a $1.1 Million Cost Realignment With the Department of Defense Marketwired
Sep-28-16 09:41AM  ETFs with exposure to Cleveland BioLabs, Inc. : September 28, 2016 Capital Cube
09:41AM  ETFs with exposure to Cleveland BioLabs, Inc. : September 28, 2016
Sep-12-16 10:38AM  ETFs with exposure to Cleveland BioLabs, Inc. : September 12, 2016
Aug-30-16 11:00AM  ETFs with exposure to Cleveland BioLabs, Inc. : August 30, 2016
Aug-19-16 12:43PM  ETFs with exposure to Cleveland BioLabs, Inc. : August 19, 2016
Aug-18-16 10:43AM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016 Capital Cube
10:43AM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016
Aug-15-16 08:42AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
08:30AM  Cleveland BioLabs Reports Second Quarter 2016 Financial Results and Development Progress Marketwired
Jul-22-16 04:22PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers
Jul-21-16 06:05AM  CLEVELAND BIOLABS INC Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta
Jul-19-16 12:08PM  ETFs with exposure to Cleveland BioLabs, Inc. : July 19, 2016
Jul-12-16 04:25PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand
09:00AM  Cleveland BioLabs Announces Board Resignations Marketwired
May-17-16 12:26PM  Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q1, 2016 By the Numbers
May-16-16 07:30AM  Cleveland BioLabs Reports First Quarter 2016 Financial Results and Development Progress Marketwired
May-12-16 02:40PM  22nd Century to begin cannabis research at new medical campus labs at bizjournals.com
May-06-16 05:55PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit
Apr-15-16 03:05PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Apr-04-16 07:30AM  Cleveland BioLabs Announces Webcast of Annual Meeting Marketwired
Mar-16-16 02:50PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Other Events
02:00PM  Cleveland BioLabs Provides Update on Pre-EUA Review of Entolimod as Radiation Countermeasure Marketwired
Feb-23-16 05:04PM  CLEVELAND BIOLABS INC Files SEC form 10-K, Annual Report
Feb-22-16 10:35AM  CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition
07:30AM  Cleveland BioLabs Reports 2015 Financial Results and Development Progress Marketwired
Feb-09-16 07:30AM  Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute Marketwired
Feb-02-16 08:00AM  Cleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation Marketwired
Jan-26-16 07:49AM  Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation at noodls
07:30AM  Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation Marketwired
Jan-22-16 03:25PM  Cleveland BioLabs Gets Orphan Status for Entolimod in EU
Jan-21-16 07:30AM  Cleveland BioLabs Attains Orphan Drug Status From the EMA for Entolimod as a Radiation Countermeasure
Dec-24-15 01:04PM  CLEVELAND BIOLABS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Defin
Dec-22-15 07:30AM  Cleveland BioLabs and Rusnano Make Additional Investments in Panacela Marketwired
Dec-16-15 01:16PM  Cleveland BioLabs, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.